Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California

Paulo Telles Dias¹,², Judith A Hahn³, Eric Delwart⁴, Brian Edlin⁵, Jeff Martin⁵,⁵, Paula Lum⁷, Jennifer Evans², Alex Kral⁸, Steve Deeks⁷, Michael P Busch⁴,⁹ and Kimberly Page²,⁶*

Abstract

Background: Hepatitis C virus (HCV) genotype (GT) has become an important measure in the diagnosis and monitoring of HCV infection treatment. In the United States (U.S.) HCV GT 1 is reported as the most common infecting GT among chronically infected patients. In Europe, however, recent studies have suggested that the epidemiology of HCV GTs is changing.

Methods: We assessed HCV GT distribution in 460 patients from three HCV-infected high risk populations in San Francisco, and examined patterns by birth cohort to assess temporal trends. Multiple logistic regression was used to assess factors independently associated with GT 1 infection compared to other GTs (2, 3, and 4).

Results: Overall, GT 1 was predominant (72.4%), however younger injection drug users (IDU) had a lower proportion of GT 1 infections (54.7%) compared to older IDU and HIV-infected patients (80.5% and 76.6%, respectively). Analysis by birth cohort showed increasing proportions of non-GT 1 infections associated with year of birth: birth before 1970 was independently associated with higher adjusted odds of GT 1: AOR 2.03 (95% CI: 1.23, 3.34). African-Americans as compared to whites also had higher adjusted odds of GT 1 infection (AOR: 3.37; 95% CI: 1.89, 5.99).

Conclusions: Although, HCV GT 1 remains the most prevalent GT, especially among older groups, changes in GT distribution could have significant implications for how HCV might be controlled on a population level and treated on an individual level.

Keywords: hepatitis C virus, HCV, GT, injection drug use, HIV, birth cohort, African-American

Background

Hepatitis C virus (HCV), first identified in 1990, is a single strand RNA virus in the family Flaviviridae. It is prone to high rates of genetic mutation, resulting in evolution to divergent forms and six major genotypes [1]. Each genotype (GT) is further divided into subtypes, based on genetic sequence variability. There are notable clinical differences in responsiveness to interferon-based therapy for treatment of chronic infection by GT, with GTs 1 and 4 being less responsive and requiring longer exposure time to treatment than types 2 and 3 [2-5]. GT has been associated with different patterns in HCV viremia during interferon treatment [6], and antiviral resistance [7,8]. Although some clinical conditions have been noted to differ by HCV GT, including insulin resistance [9], HIV and HIV disease progression [10], little is known regarding how different HCV GTs differ in virulence or pathogenicity [11]. African Americans infected with GT 1 are significantly less likely to respond to HCV treatment than Asian and Caucasian patients with GT 1 [12,13]. Patients infected with GT 1 who carry a genetic variant allele near IL28B gene are more likely to respond to combination therapy (pegylated interferon-alpha-2a or -2b and ribavirin) [14] and clear spontaneously [15]. As this polymorphism varies by race [14],
Methods
We examined data from three prospective cohort studies in San Francisco, California, U.S. In total, 460 chronically HCV infected persons were included from the following studies, all with IDU exposure: 1) The “Urban Health Study” (UHS), a prospective serial cross-sectional study of IDU recruited from San Francisco neighborhoods with high prevalence of IDU[25]; 2) The UFO Study, a prospective cohort study on the incidence of HCV infection in young (<30 years) street-recruited IDU[26]; 3) The “Study of the Consequences of the Protease Inhibitor Era” (SCOPE) Study, a prospective, observational study of HIV positive patients[27]. Subjects included in this study were recruited over varying intervals during a twenty-year time period between 1987 and 2007 (Table 1). HCV GT was assessed in the participants with incident HCV infection in the UFO Study and the UHS using stored sera specimens from blood samples taken at the visit of first HCV detection (anti-HCV or HCV RNA). In the SCOPE study HCV GT was determined from stored samples of prevalent infection obtained at first or second study visit (if not available from the first study visit).

In all studies anti-HCV and HCV viremia were assessing using Ortho EIA 3.0, with confirmation by RIBA 3.0, Chiron, Corp, and a discriminatory HCV transcription-mediated amplification (dHCV TMA) assay component of the Procleix HIV-1/HCV assay (Novartis Diagnostics, Emeryville, CA, USA), respectively. HCV GT was determined by the LiPA Line Probe Assay (Bayer Diagnostics, Tarrytown, NY, USA). Indeterminate GTs and co-infected cases were not included in the final analysis of the study.

We assessed differences between the study groups and between GT 1 versus other GTs with respect to sociodemographic and clinical variables using standard methods. Differences in proportions were compared using Pearson Chi-Square tests. Differences in variables with continuous data were assessed by comparing medians and distributions using the Kruskal-Wallis test. We examined HCV GT distribution by birth cohort to assess trends by 10-year birth intervals using the Mantel-Haenszel Chi-Square test for trend. Multiple logistic regression was used to assess factors independently associated with GT 1 infection compared to other GTs (2, 3, and 4); adjusted odds ratios (AOR) and 95% Confidence Intervals (CI) were calculated. Models were constructed in an iterative backwards stepwise manner. All variables with a p-value <= 0.05 at the bivariate level were entered into the model and removed one by one. Variables with a p-value of <= 0.10 were retained in the final model. All analyses were conducted using SPSS for Windows statistical software package (version 13).

All of the research from participating studies in this project was conducted under protocols reviewed and approved by the University of California San Francisco Human Subjects Research Committee, and conformed to the Helsinki Declaration and local regulations. All study subjects gave informed consent for participation.

Results
Of the 460 persons included, 202 (43.9%) were from the UHS; 128 (27.8%) from UFO; and 130 (28.3%) from the SCOPE studies. Table 1 shows participant characteristics by study. There were significant differences in age, race/ethnicity and educational background between the three groups, and males comprised the majority (69.4%) in all. GT 1 was predominant (72.4%) overall, however between groups the distribution of GTs was significantly different. Young IDU (the UFO Study) had the lowest proportion of GT 1 infections (54.7%) compared to older IDU (UHS) and HIV-infected patients (SCOPE) who had 80.5% and 76.6%, respectively. Analysis by birth cohort also showed significant differences (see Figure 1). The more recent birth cohorts had increasing proportions of non-GT 1 infections compared to less recent birth cohorts, and young IDU specifically had more GT 3 infections compared to other birth cohorts. The more recent birth cohorts had increasing proportions of non-GT 1 infections compared to less recent birth cohorts, and young IDU specifically had more GT 3 infections compared to others (Table 1). Table 2 shows the bivariate and multivariate results of variables associated with GT 1 infection compared to GTs 2, 3, and 4 (non-GT 1) infection. Factors independently associated with prevalent infection with HCV GT 1 included birth cohort and race/ethnicity. Patients born before 1970 had higher adjusted odds of GT 1 infection compared to those born more recently: AOR 2.03 (95% CI: 1.23, 3.34); age and study group were not included in the final model due to collinearity with birth cohort. African-Americans compared to Caucasian patients were more likely to have GT 1: AOR 3.37 (95% CI: 1.89, 5.99).
Discussion

These results suggest that in San Francisco, within the ongoing HCV epidemic, the epidemiology of infecting HCV viruses has changed over time. Among younger IDU, who are also more likely to have more recent infection, non-GT 1 is increasingly prevalent. Historically, few studies have been published describing GTs in San Francisco patients. In 1999, Gish et al. [28] described GTs (using restriction fragment length polymorphism analysis) in 186 patients with chronic HCV.

Table 1 Selected characteristics of participants in three studies of HCV infection in San Francisco (N = 460)

| Variables               | UHS   | UFO   | SCOPE  | Total all studies |
|-------------------------|-------|-------|--------|-------------------|
| Total N                 | 202   | 128   | 130    | 460               |
| Gender N(%)             |       |       |        |                   |
| Male                    | 145 (72.5%) | 88 (68.8%) | 85 (65.4%) | 318 (69.4%)       |
| Female                  | 55 (27.5%)  | 40 (31.2%)  | 45 (34.6%)  | 140 (30.6%)       |
| Age (in years)#         |       |       |        |                   |
| Median                  | 47.0  | 22.3  | 45.0   | 43.0              |
| IQR                     | 42.3-50.0 | 19.9-25.0 | 40.8-49.0 | 28.0 - 48.0       |
| Years of recruitment    | 1987-1998 | 2000-2007 | 2000-2007 | 1987-2007         |
| HCV Genotypes* ¶        |       |       |        |                   |
| Type 1                  | 161 (80.5%) | 70 (54.7%) | 10 (8.2%)  | 50 (11.1%)        |
| Type 2                  | 22 (11.0%)  | 18 (14.1%)  | 15 (12.3%)  | 69 (15.3%)        |
| Type 3                  | 15 (7.5%)   | 39 (30.5%)  | 2 (1.6%)    | 5 (11.1%)         |
| Type 4                  | 2 (1.0%)    | 1 (0.8%)    | 122 (100%)  | #***              |
| HCV Genotypes*¶         |       |       |        |                   |
| 1                       | 15 (7.4%)  | 32 (25.0%)  | 62 (47.7%)  | 110 (23.9%)       |
| 1a                      | 76 (37.6%) | 26 (20.3%)  | 3 (2.3%)    | 105 (22.8%)       |
| 1a/1b                   | 5 (2.5%)   | 1 (0.8%)    | 4 (3.1%)    | 10 (2.2%)         |
| 1b                      | 65 (32.2%) | 11 (8.6%)   | 26 (20.0%)  | 101 (22.0%)       |
| 1/2                     | 1 (0.5%)   | 0 (0.0%)    | 0 (0.0%)    | 1 (0.2%)          |
| 2                       | 1 (5.0%)   | 5 (3.9%)    | 0 (0.0%)    | 5 (1.1%)          |
| 2a                      | 0 (0.0%)   | 1 (0.8%)    | 0 (0.0%)    | 1 (0.2%)          |
| 2a/2c                   | 4 (2.0%)   | 6 (4.7%)    | 2 (1.5%)    | 12 (2.6%)         |
| 2b                      | 17 (8.4%)  | 6 (4.7%)    | 3 (2.3%)    | 26 (5.7%)         |
| 2b/3a                   | 1 (0.5%)   | 0 (0.0%)    | 0 (0.0%)    | 1 (0.2%)          |
| 3a                      | 15 (7.4%)  | 39 (30.5%)  | 15 (11.5%)  | 69 (15.0%)        |
| 4                       | 1 (0.5%)   | 0 (0.0%)    | 1 (0.8%)    | 40(0.9%)          |
| 4c/4d                   | 1 (0.5%)   | 1 (0.8%)    | 1 (0.8%)    | 3(0.7%)           |
| Undetermined            | 0 (0.0%)   | 0 (0.0%)    | 8 (6.2%)    | 8 (1.7%)**        |
| Ethnicity¶              |       |       |        |                   |
| Caucasian               | 55 (27.5%) | 97 (75.8%) | 54 (41.5%) | 205 (44.8%)       |
| African Amer.           | 124 (62.0%) | 2 (1.6%)   | 54 (41.5%) | 180 (39.3%)       |
| Latino                  | 10 (5.0%)  | 7 (5.5%)    | 9 (6.9%)    | 26 (5.7%)         |
| Asian                   | 1 (0.5%)   | 1 (0.8%)    | 3 (2.3%)    | 5 (1.1%)          |
| Other                   | 10 (5.0%)  | 21 (16.4%)  | 10 (7.7%)   | 42 (9.2%)**       |
| Education (1)¶          |       |       |        |                   |
| < High School           | 56 (28.0%) | 67 (52.8%) | 34 (26.2%) | 157 (34.4%)       |
| >= High school          | 144 (72.0%) | 60 (47.2%) | 96 (73.8%) | 300 (65.6%)**     |

* Co-infected cases not included.
** Statistically significant difference (p < 0.05)
# Age at the time of the interview
¶ Some cells do not conform to the total sample size totals due to missing data
¶* 2 people co-infected with different genotypes were not included
¶** 8 people with undetermined genotypes were not included
¶*** 10 people not included due to undetermined genotypes or to co-infection with different genotypes.
the majority presumptively IDU); 76% were type 1 (1a, 41%; 1b, 35%), 13% were type 2 (2a, 3%; 2b, 10%) and 11% were type 3a. In that sample, HCV GT was not associated with age, gender, ethnic origin, or presumptive mode of transmission. In two small groups (n = 8 each) of chronically HCV infected, active and former IDU recruited from two urban San Francisco Hospitals, 75% of active IDU (median age 47 years) and all of the former IDU (median age 49) were type 1. As patients in these studies were more heterogeneous with respect to routes of exposure, and were likely to have been infected some years before clinical assessment, these data are consistent with the suggestion that type 1 GTs were more prevalent in San Francisco IDU in the 1990’s.

In Europe, Simmonds et al [29] showed an association between HCV GT and age, and attributed it primarily to risk exposure differences. In Germany, Schroter et al [24] also showed increases in GTs 3a in younger groups, including IDU and non-IDU, leading these authors to hypothesize that the introduction of new subtypes in a high risk group may rapidly impact lower risk groups. Others have shown differences in HCV GT distribution by route of exposure, with GT 3a associated with injection exposures, and GT 1b associated with acquisition through blood transfusion [21,22,30,31]. In a multicentre study of HCV infection in 183 HIV-infected IDU sampled between 1984 and 2001, Van Asten et al [32], using phylogenetic analyses, found that subtypes 3a and 1a were most prevalent (38.3%, and 36%, respectively) and extensively dispersed throughout the countries.

The relative differences in HCV GT seen in these San Francisco patients may be due to various factors, including temporal changes in the dominant circulating virus, or potentially separate epidemics marked by differential social mixing. All three populations were sampled in San Francisco and were at high risk of HCV due to parenteral exposure, but younger patients had significantly lower odds of being infected with GT 1. African-Americans represented 62% of older IDU, only 1.9% of younger IDU, and 41.6% of HIV co-infected patients, but controlling for birth year and other factors, still had

### Table 2: Bivariate and multivariate associations between selected demographic characteristics and infection with HCV genotype 1 vs. non-1 (genotypes 2, 3, 4)

| Characteristic          | % with genotype 1 HCV infection | Odds Ratio (95% CI) | p-value | Adjusted# Odds Ratio (95% CI) | p-value |
|-------------------------|---------------------------------|---------------------|---------|-------------------------------|---------|
| Gender                  |                                 |                     |         |                               |         |
| Male                    | 73.4                            | 1.22 (0.78, 1.90)   | 0.38    |                               |         |
| Female                  | 69.3                            |                     |         |                               |         |
| Ethnic Background       |                                 |                     |         |                               |         |
| Caucasian               | 59.2                            | 1                   |         |                               |         |
| African American        | 87.1                            | 4.65 (2.75, 7.86)   | < 0.001 | 3.37 (1.89, 5.99)             | <0.001  |
| Latino                  | 72.0                            | 1.77 (0.71, 4.45)   | 0.22    | 1.57 (0.61, 3.98)             | 0.35    |
| Other                   | 62.8                            | 1.16 (0.59, 2.30)   | 0.66    | 1.85 (0.59, 2.37)             | 0.63    |
| Birth Cohort            |                                 |                     |         |                               |         |
| Born before 1970        | 79.0                            | 2.97 (1.20, 4.59)   | < 0.001 | 2.03 (1.23, 3.34)             | 0.006   |
| Born 1971 or later      | 56.0                            |                     |         |                               |         |
| Study group             |                                 |                     |         |                               |         |
| UFO                     | 54.7                            | 1                   |         |                               |         |
| UHS                     | 80.5                            | 3.33 (2.04, 5.45)   | < 0.001 |                               |         |
| SCOPE                   | 76.7                            | 2.92 (1.68, 5.06)   | < 0.001 |                               |         |

** study group was not included in the model as [UFO vs. (UHS and SCOPE)].
# variables included in the final model were: Ethnic Background and Birth Cohort
significantly higher odds of subtype 1 HCV infection compared to Caucasian patients. This differential GT distribution by racial group may be due to various factors including temporal, social (mixing), differential access to prevention, and/or possibly genetic explanations. The prevalence of IDU has decreased among younger age groups and among African-American populations in the U.S. [33], and drug injector networks and associated risks may influence the spread of HCV GTs [34,35] as seen with other diseases [36]. Risk groups, in particular IDU compared to non-IDU populations, may have differential access to prevention methods by age, race or other factors that might result in differences in HCV transmission patterns or detection [37-39]. The genetic polymorphism recently associated with treatment and spontaneous clearance of HCV [14,40] occurs with less frequency in African populations, and may account for some of the relative differences seen in HCV GTs prevalence in African Americans and possibly other racial/ethnic groups [19].

To our knowledge no studies have examined GT distribution patterns over several age groups (or by birth cohort) and risk group. In Spain, Serra et al (40), found that GTs varied by risk group: IDU were less likely to be infected with GT 1b and more likely to be infected with GTs 1a and 3, compared to transfusion recipients and blood donors, and GT prevalence varied over time in all groups [41]. Our results are also consistent with others who have shown that African-Americans are more likely to be infected with HCV GT 1 [18,19]. Significantly, a very recent report analyzing over 22,000 samples from HCV infected patients at a national reference laboratory in the U.S., found that patients infected with GT 3 were significantly younger (P<0.0001) than those with non-GT 3 (1, 2, or 4), the frequency of HCV GT 3 ranged from just 4.3% in subjects over age 70 to 20.6% in those age 21 to 30 [42]. Our results are consistent with these new findings, and among the first to suggest that the relative prevalence of GT 3 may be increasing as younger groups are more likely to have been recently infected.

This study has some limitations that should be acknowledged. Genotyping was performed by reverse hybridization, and viruses were not sequenced; misclassification could have occurred [43]. Patients may also be infected with multiple GTs, especially IDU who have frequent opportunities for exposure [44], and the assay would have only identified the dominant virus [45]. The groups here are selected from studies of high risk populations in San Francisco, so results may not be generalizable to other risk groups. Finally, two groups (UHS and SCOPE) predominantly represent chronically infected patients, and samples were genotyped only if HCV RNA was present. If there is differential spontaneous clearance in association with HCV GT [26], these results would not reflect the circulating infecting GTs in acutely infected patients, but only those in chronically infected groups.

Conclusions

IDU are the population most at risk for HCV in the U.S. and younger IDU are most likely to present with more recently acquired infection. Although GT 1 remains the most prevalent GT, especially among older groups, changes in GT distribution coupled with changes in the demography of injection drug use [33] could have important implications for the HCV epidemic. From a public health perspective, these findings might have significant implications for how blood borne virus infections could be controlled on a population level and how they are treated on an individual level.

Acknowledgements

The following sources of funding supported the investigators and studies participating in this project: U.S. National Institutes for Health (NIH) (R01-DA016017-03A1, U19-AI40034-13, R01-DA023365; UL1-RR024131, P30-AI27763, R01-DA09532, R01-DA12109, R01-DA13245, R01-DA021550, N01-CO-12400); the Substance Abuse and Mental Health Services Administration (H79-T112103), and the San Francisco Department of Public Health (POHC90001316). Dr. Telles was supported by NIDA Invest Fellowship linked to 2 R01 DA016017-03A1. We also acknowledge the UCSF Liver Center NIH P30 DK026743.

Author details

1Núcleo de Estudos e Pesquisas em Atenção ao Uso de Drogas (NEPAD): Universidade do Estado do Rio de Janeiro (State University of Rio de Janeiro), R Fonseca Teles 121, 4° Andar, 20940-200 Rio de Janeiro, RJ, Brasil. 2Department of Epidemiology and Biostatistics, Division of Preventive Medicine and Public Health, Box 1224, 50 Beale Street 1200 University of California San Francisco, San Francisco, CA USA. 3Department of Medicine, Division of Infectious Disease, San Francisco General Hospital, Box 0811, SFGH Bldg 100 335; University of California San Francisco, San Francisco, CA. 4Department of Medicine, SUNY Downstate Medical Center, College of Medicine, 450 Clarkson Avenue, Box 1240, Brooklyn, NY 11203. USA. 5Department of Epidemiology and Biostatistics, Division of Clinical Epidemiology, Box 0560, 185 Berry Street 5700, University of California San Francisco, San Francisco, CA. 6Department of Medicine, Positive Health Program, San Francisco General Hospital, Box 0874, SFGH Bldg 100 335; University of California San Francisco, San Francisco, CA. 7Department of Laboratory Medicine, Box 0134, University of California San Francisco San Francisco, CA. 8Research Triangle Institute (RTI), San Francisco, CA USA.

Authors’ contributions

All authors made substantive intellectual contributions to the study, including to conception and design, or acquisition of data, or analysis and interpretation of data, and drafting or revising the manuscript. All authors read and approved the final manuscript. PTD participated in the study conception, data analysis and drafting of the manuscript. JAH participated in study design, acquisition and analysis of data, and manuscript revisions. ED, RE, JM, ST, PL, JE, AK, SD and MB participated in study design, data acquisition, and drafting the manuscript. KP conceived of the study, participated in data collection and analyses, and the drafting and finalizing of the manuscript.

Competing interests

The authors declare that they have no competing interests.
Received: 27 January 2011 Accepted: 2 August 2011
Published: 2 August 2011

References

1. Simmonds P, Bukh J, COMPETETIVE. Deleage G, Enomoto N, Feinstone S, Feller C, Fleming J, Feinstone S, et al. Clinical significance of hepatitis C virus genotypes and hepatitis C virus infection. N Engl J Med 2002, 347(1):975-982.
2. Manns MP, McHutchison JG, Gordon SC, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):955-965.
3. Chiolero A, Billeaud E, Viallon V, Boroujerdi A, et al. Peginterferon alfa-2b and ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2002, 360(9339):2265-2271.
4. McHugh MC, Gordon JF, Schiff ER, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998, 339(21):1485-1492.
5. Page K, Hahn JA, Evans J, Shibuski S, LeMert D, Lefaivre N, et al. Peginterferon alfa-2b and ribavirin in treatment-naive genotypically mixed patients. J Clin Infect Dis 2002, 38(4):450-456.
6. Simmonds P, Bukh J, Deleage G, Enomoto N, Feinstone S, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2002, 358(9286):955-965.
7. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, galai N, Nolt K, et al. Peginterferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998, 339(21):1485-1492.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):955-965.
9. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, galai N, Nolt K, et al. Peginterferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998, 339(21):1485-1492.
10. Page K, Hahn JA, Evans J, Shibuski S, LeMert D, Lefaivre N, et al. Peginterferon alfa-2b and ribavirin in treatment-naive genotypically mixed patients. J Clin Infect Dis 2002, 38(4):450-456.
11. Simmonds P, Bukh J, Deleage G, Enomoto N, Feinstone S, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2002, 358(9286):955-965.
12. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, galai N, Nolt K, et al. Peginterferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998, 339(21):1485-1492.
13. Page K, Hahn JA, Evans J, Shibuski S, LeMert D, Lefaivre N, et al. Peginterferon alfa-2b and ribavirin in treatment-naive genotypically mixed patients. J Clin Infect Dis 2002, 38(4):450-456.
14. Simmonds P, Bukh J, Deleage G, Enomoto N, Feinstone S, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2002, 358(9286):955-965.
15. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, galai N, Nolt K, et al. Peginterferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998, 339(21):1485-1492.
16. Page K, Hahn JA, Evans J, Shibuski S, LeMert D, Lefaivre N, et al. Peginterferon alfa-2b and ribavirin in treatment-naive genotypically mixed patients. J Clin Infect Dis 2002, 38(4):450-456.
17. Simmonds P, Bukh J, Deleage G, Enomoto N, Feinstone S, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2002, 358(9286):955-965.
18. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):955-965.
19. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, galai N, Nolt K, et al. Peginterferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998, 339(21):1485-1492.
20. Page K, Hahn JA, Evans J, Shibuski S, LeMert D, Lefaivre N, et al. Peginterferon alfa-2b and ribavirin in treatment-naive genotypically mixed patients. J Clin Infect Dis 2002, 38(4):450-456.
34. Bluthenthal RN, Do DP, Finch B, Martinez A, Edlin BR, Kral AH. Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. J Urban Health 2007, 84(5):653-666.

35. Johnson RA, Gerstein DR, Pach A, Cerbone FG, Brown J. HIV risk behaviors in African-American drug injector networks: Implications of injection-partner mixing and partnership characteristics. Addiction 2002, 97(8):1011-1024.

36. Friedman SR, Lieb S, Tempalski B, Cooper H, Keem M, Friedman R, Flom PL. HIV among injection drug users in large US metropolitan areas, 1998. J Urban Health 2005, 82(3):434-445.

37. Cooper HL, Bossak BH, Tempalski B, Friedman SR, Des Jarlais DC. Temporal trends in spatial access to pharmacies that sell over-the-counter syringes in New York City health districts: relationship to local racial/ethnic composition and need. J Urban Health 2009, 86(6):929-945.

38. Henzaeling KG, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, Asch SM, Bluthenthal RN. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes. J Subst Abuse Treat 2007, 32(4):423-429.

39. Stopka TJ, Garfein RS, Ross A, Truax SR. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health 2007, 84(1):116-125.

40. Thomas EL, Thio CL, Martin MP, Qi Y, Ge D, O’Huiern C, Kidd J, Kidd K, Khakoo SJ, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009.

41. Serra MA, Rodriguez F, del Olmo JA, Escudero A, Rodrigo JM. Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 2003, 10(3):183-188.

42. Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD. Hepatitis C Virus Genotypes in Clinical Specimens Tested at a National Reference Testing Laboratory in the United States. J Clin Microbiol 2011.

43. Nadasadj R, Khan GT, Miller SA, Brooks GF. Evaluation of a new-generation line-probe assay that detects 5' untranslated and core regions to genotype and subtype hepatitis C virus. Am J Clin Pathol 2007, 128(2):300-304.

44. Herring BL, Page-Shafer K, Tobler LH, Delwart EL. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 2004, 190(8):1396-1403.

45. Schroter M, Feucht H-H, Zoliner B, Schafer P, Laufs R. Multiple infections with different HCV genotypes: prevalence and clinical impact. J Clin Virol 2003, 27(2):200-204.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/11/208/prepub

doi:10.1186/1471-2334-11-208
Cite this article as: Dias et al.: Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infectious Diseases 2011 11:208.